STAR Trial for Atrial Functional Mitral Regurgitation

Randomised, open-label trial in atrial functional mitral regurgitation (AFMR) (2 arms), sponsored by Beijing An Zhen Hospital. Primary endpoints: Time to first occurrence of a composite event of death from any cause, hospitalization for worsening heart failure or unplanned outpatient worsening heart failure event at 24 months and Number of participants with the primary safety endpoint at 30 days. Started Jun 2026; status: recruiting.